170 results about "Phagocytosis" patented technology

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

The invention belongs to the field of biological medicines, and relates to a drug-loaded nano-vesicle as well as a preparation method and application thereof. The drug-loaded nano-vesicle comprises a vesicle core and a drug-loaded nano-vesicle, wherein the vesicle core comprises siRNA (small interfering Ribonucleic Acid) capable of specifically targeting and silencing an NR1D1 gene; the vesicle membrane is formed by fusing an erythrocyte membrane, a macrophage membrane, cardiolipin, cholesterol and lecithin. The drug-loaded nano-vesicle can specifically target macrophages in a sepsis immunosuppression stage, has an intracellular response release function, recovers BMAL1 and IGF2BP2-ATP6V1B2 / ATP6V0c axis functions by inhibiting NR1D1 expression, reconstructs a macrophage phagocytosis function and lysosome-dependent bacterium removal capability, and can be used for preparing a drug-loaded nano-vesicle with a specific targeting function. The survival rate of sepsis immunosuppression model animals is obviously improved; and the bacterial load is reduced. Compared with a traditional electroporation method, the preparation method disclosed by the invention has the advantage that the encapsulation efficiency of siRNA is remarkably improved.

Provided are a postbiotic of Weizmannia coagulans, and a preparation method therefor, and a use thereof. The postbiotic comprises inactivated bacteria and / or lipoteichoic acid. The postbiotic can enhance the phagocytosis activity of macrophages, the cytokine and NO secretion ability of macrophages, and the expression levels of immune-function-related genes and proteins, and has an effect of inducing human PBMC cells to kill cancer cells.

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The application provides a momordica root polysaccharide and a preparation method and application thereof, and belongs to the technical field of natural product development. The preparation method of the momordica root polysaccharide comprises the following steps: drying and crushing momordica roots, and removing fat by ethanol reflux; after water extraction and alcohol precipitation, and removing protein, a momordica root crude polysaccharide is obtained; and the momordica root crude polysaccharide is sequentially separated and purified by DEAE-52 cellulose column and Sephadex LH20 gel column to obtain the momordica root refined polysaccharide. The preparation method has the advantages that the polysaccharide obtained by directly extracting water in the prior art has a narrow molecular weight distribution range and better immune enhancement activity. Experimental results show that the momordica root polysaccharide can stimulate RAW264.7 cells to secrete NO, TNF-alpha and IL-6 factors, enhance the phagocytosis of RAW264.7 cells, and thus enhance the cell immune function, and can be applied to the development of products for improving immunity.

The invention belongs to the technical field of biological medicine, and relates to application of a compound D25, in particular to application of a small molecule compound D25 in preparation of a product for preventing or treating Alzheimer's disease (AD), and the structural formula of the compound is shown in the specification. Experiments prove that the small molecule compound D25 can pass through a blood brain barrier, can induce autophagy, can relieve pathological characteristics of an AD mouse model and improve cognitive impairment of the AD mouse model, can reduce the proportion of disease-related microglial cells by recovering the morphology of the microglial cells and improving the A beta phagocytosis capacity of the microglial cells, has the potential of promoting neuronal growth and increasing the number of protrusions, and can be used for preparing a medicine for treating the disease-related microglial cells. Therefore, AD can be effectively treated, the safety is high, the effect is achieved, and the application prospect is great.

The invention discloses a Streptomyces rochei D74 homogeneous polysaccharide and a preparation method and application thereof.The Streptomyces rochei D74 homogeneous polysaccharide is obtained by smashing Streptomyces rochei D74 mycelia obtained through liquid fermentation, then conducting water extraction, concentration, alcohol precipitation and deproteinization to obtain crude polysaccharide, and further conducting ion-exchange chromatography, dialysis and gel column chromatography purification to obtain the Streptomyces rochei D74 homogeneous polysaccharide. The method is simple and efficient, and the obtained streptomyces homogeneous polysaccharide remarkably inhibits proliferation of human gastric cancer cells SGC-7901 by inducing tumor cell apoptosis; meanwhile, immune cells RAW264.7 can be activated, the phagocytic ability and the nitric oxide (NO) release ability of the immune cells RAW264.7 can be improved, and the polysaccharide can become a potential polysaccharide drug for treating human liver cancer.

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The embodiment of the invention discloses a heavy chain variable region and a light chain variable region of an anti-GPC3 monoclonal antibody and application of the heavy chain variable region and the light chain variable region. The high-affinity anti-GPC3 sequence is obtained through screening, the binding specificity of the high-affinity anti-GPC3 sequence and the GPC3 antigen is high, and dissociation is slow. The sequence is used as an extracellular targeting domain to construct GPC3-CAR, after macrophages are transduced through lentivirus, CAR-M can specifically recognize GPC3 positive target cells, activate intracellular signal channels and remarkably improve in-vitro phagocytosis and killing activity, the hepatoma cell lysis effect is better, and technical support is provided for anti-hepatoma application.

The invention discloses an application of abscisic acid in preparation of a medicine for improving secondary brain injury after cerebral hemorrhage, the abscisic acid can relieve neuroinflammation and improve neurological function recovery by repairing microglial cell lysosome functions, enhancing phagocytic ability and promoting hematoma removal, and a new medicine strategy is provided for cerebral hemorrhage treatment.

The invention discloses a whitening composition as well as a preparation method and application thereof. The whitening composition is prepared from the following components: a tea leaf extract, a lavender flower extract and water, wherein the tea leaf extract, the lavender flower extract and the water are added into the whitening composition. The whitening composition can interact and synergistically improve the autophagy ability of cells, synergistically improve the phagocytosis of melanin in keratinocytes and the removal ability of skin metabolic wastes, can synergistically inhibit the generation of melanin and synergistically improve the expression of miR-137 genes in melanocytes, has a relatively high development prospect of cosmetics with whitening effects, and has a wide application prospect. Moreover, the composition is mild in property, easy to absorb and non-irritant, and can be widely applied to skin care cosmetics.

The invention discloses an application of a pyruvate dehydrogenase kinase (PDKS) inhibitor in preparation of a composition for treating Alzheimer's disease (AD), and particularly discloses an application of the PDKs inhibitor in preparation of the composition for treating the AD. According to the invention, the level of oxidative phosphorylation (OXPHOS) of microglial cells is obviously enhanced, the inflammatory response of the microglial cells is effectively reduced, the migration and aggregation capabilities of the microglial cells are obviously improved, the capability of the microglial cells to phagocytize and degrade extracellular beta-amyloid protein (A beta) plaque is obviously enhanced, the cognitive function defect of AD model mice is effectively improved, and the application of the microglial cells in the treatment of the AD model mice is promoted. The preparation is simple, and the application is wide.

This invention provides the application of triptolide in the preparation of drugs for treating microglial inflammation-related neuroimmunological disorders. Experiments show that triptolide significantly inhibits the expression, migration, phagocytosis, and morphological activation of microglial inflammatory factors, and exerts an anti-microglial inflammatory effect in animal models. Through DARTS technology combined with siRNA screening, ACOX1 was identified as its key target, and the direct binding between the two was verified by CETSA, SPR, and molecular docking.

The present disclosure addresses the problem of providing technology for phagocytizing unwanted cells or the like in vivo.　This protein includes, from the N-terminus to the C-terminus, (A) a target binding region that binds to a target, and (C) an SHBG-like domain of ProS.

Compositions and methods that are useful for inducing phagocytosis of a cancer cell and / or increasing killing of a cancer cell (e.g., by an immune cell) by contacting the cancer cell with an antibody capable of selectively binding to a CD43 protein expressed on the surface of cancer cells. In various embodiments, the CD43 protein is not expressed on the surface of a healthy cell.

The present invention relates to the technical field of immune engineering, and in particular to a CD155-targeting antibody or antigen-binding fragment and a use thereof. The antibody comprises a heavy chain variable region having at least 70% identity to a sequence shown in SEQ ID NO: 23 and a light chain variable region having at least 70% identity to a sequence shown in SEQ ID NO: 24, or a heavy chain variable region having at least 70% identity to a sequence shown in SEQ ID NO: 25 and a light chain variable region having at least 70% identity to a sequence shown in SEQ ID NO: 26. The antibody has an excellent binding capability with CD155, and CAR-T cells constructed on the basis of the antibody have a significant killing capability against tumor cells expressing CD155, as well as an obvious cellular internalization effect, the capability of promoting the cytotoxic effect of NK cells, and the capability of promoting the phagocytosis effect of macrophages, thereby exhibiting an excellent anti-tumor effect.

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.

The invention discloses an application of a DHA-RXR-PPAR signal channel in promotion of postoperative recovery of hysteromyoma after HIFU (high intensity focused ultrasound). Clinical sample metabolic spectrum analysis and in-vitro cell function experiments are combined, and research proves that the differential metabolite DHA drives macrophage metabolism reprogramming through an RXR-PPAR signal axis, so that the macrophage is promoted to be transformed into an anti-inflammatory and phagocytosis-promoting repair phenotype, the absorption and repair process of the HIFU postoperative hysteromyoma is accelerated, and the treatment effect of the HIFU postoperative hysteromyoma is improved. A new intervention target spot (RXR-PPAR gamma axis) and a new potential medicine are provided for HIFU (high intensity focused ultrasound) postoperative rehabilitation.

The application belongs to the technical field of molecular biology and medicine, and discloses a methylation marker for detecting the benignity and malignancy of thyroid nodules and an application. 780 new methylation sites are identified, 273 tumor occurrence and development related genes are associated, and the Fc gamma R-mediated phagocytosis signal pathway is involved. The methylation marker for detecting the benignity and malignancy of thyroid nodules comprises multiple genes and multiple methylation sites. The methylation level of multiple genes and multiple sites is detected, the problem of low and unstable methylation signal of single gene or single site is overcome, and thus the sensitivity and specificity of detection are improved.

The invention discloses a cascade targeted drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention designs a drug delivery system with a cascade targeting function, and the drug delivery system is used for delivering a phosphodiesterase 4 inhibitor A5. Through polypeptide modification and exosome fusion, phagocytosis and ingestion of cells to a drug delivery system are promoted, and the bioavailability of the drug is significantly improved. The drug delivery system shows excellent in-vivo lung targeting, can effectively inhibit the aggravation of inflammatory infiltration in the lung, and plays a role in treating acute lung injury. The invention provides a new strategy for improving the targeting property and the utilization rate of the medicine, provides a new medicine for treating the acute lung injury, and has a wide application prospect and an extremely high application value.

The invention relates to application of lentinan in preparation of a medicine for enhancing Kukuzhou cell immune function, and belongs to the technical field of immunopharmacology. The invention discloses a mechanism and application of lentinan LNT (Lentinan) based on a TLR2 (Toll-Liver Receptor 2) signal channel for enhancing the immune function of liver cumness cells and promoting lysosome maturation. By constructing an LNT fluorescence labeling system, a Kuptake cell in-vivo tracing model and a TLR2 function intervention model, it is proved that LNT can be directly combined with TLR2 and activate a TLR2 / MyD88 / NF-kappa B signal axis, and therefore the phagocytosis and immune response capacity of Kuptake cells is enhanced. Meanwhile, TLR2 signal-induced reactive oxygen species (ROS) up-regulation can promote TFEB dephosphorylation and nuclear translocation, lysosome maturation is driven, and degradation metabolism of LNT is accelerated. The invention provides a TLR2-based immune enhancement mechanism of the LNT, and provides a theoretical basis and an application basis for developing immunomodulatory targeted drugs.

The invention relates to the technical field of biological medicine, and particularly discloses a macrophage membrane coated plateau encephaledema drug carrier and a preparation method and application thereof, and the macrophage membrane coated plateau encephaledema drug carrier is composed of a nanoparticle core and a macrophage membrane shell layer wrapping the core; the nanoparticle core comprises an ROS-responsive carrier material and carbon monoxide release molecules MnCO entrapped in the ROS-responsive carrier material; the content of phosphatidylserine in the shell layer of the macrophage membrane is not less than 5 mol% of the total phospholipid of the membrane. According to the invention, a bionic delivery system of ROS response type MnCO nanoparticles coated with a macrophage membrane is constructed, phosphatidylserine on the surface of the membrane is utilized to actively activate a microglial cell Trem2 receptor, a positive feedback cycle of targeting phagocytosis-CO release-Trem2 up-regulation is formed, and at the same time, fatty acid oxidative metabolism reprogramming is promoted by means of degraded membrane lipid, so that the biomimetic delivery system is used for preparing the ROS response type MnCO nanoparticles. And multi-mechanism synergistic efficient brain-targeted therapy is realized.

The invention relates to the technical field of biological medicines, in particular to application of RGS1 in regulation of macrophage functions. According to the application, the antagonist for reducing the expression level of the RGS1 is used for preparing a regulating agent for increasing migration and phagocytic ability of macrophages. According to the application, a negative regulation factor RGS1 of a G protein signal channel is found to be expressed at a high level in a tissue-damaged body based on earlier-stage research, and the relevance between the expression level of the RGS1 and tissue damage can be determined through a siRNA interference agent transfection knock-down RGS1 expression experiment and a pathological section and immunofluorescence analysis experiment of a specific kidney injury model; meanwhile, by inhibiting the expression of RGS1, a macrophage related regulation pathway is activated, so that the migration and phagocytosis functions of the macrophage are enhanced.

Two push rod type linear stepping motors in the device are arranged at the two ends of a guide rail through L-shaped push rods, carrying tables are arranged above the L-shaped push rods, telescopic rotating motors are arranged on the carrying tables respectively, the telescopic rotating motors are vertically connected with magnet plates, and the magnet plates are arranged on the carrying tables. A third telescopic rotating motor is arranged at the rear end of one magnet plate, a vertical guide rail groove and a transverse guide rail groove are formed in one magnet plate, and the control module is connected with all the motors. According to the invention, the high gradient magnetic field advantage of the panel Halbach array is utilized, the precise control capability of the motor is combined, the automatic uniform field and gradient field conversion function of the device is utilized, and a microscope with an image acquisition function is matched, so that the degree of phagocytosis of magnetic particles by cells is automatically observed, and multiple sets of magnetic field devices do not need to be additionally arranged; the cell activity can be effectively protected, and the magnetic field application requirements in the fields of biomedical detection, analysis detection and the like are met.

The application belongs to the field of biological medicine, and relates to a drug-loaded nanovesicle and a preparation method and application thereof. The drug-loaded nanovesicle comprises: a vesicle core comprising siRNA capable of specifically targeting a silenced NR1D1 gene; and a vesicle membrane fused by red blood cell membranes, macrophage membranes, cardiolipin, cholesterol and lecithin. The drug-loaded nanovesicle can specifically target macrophages in the immune suppression stage of sepsis, and has an intracellular response release function. By inhibiting the expression of NR1D1, the drug-loaded nanovesicle restores the functions of BMAL1 and IGF2BP2-ATP6V1B2 / ATP6V0c axes, reestablishes the phagocytosis function of macrophages and the lysosome-dependent bacterial clearance capacity, significantly improves the survival rate of animals in a sepsis immune suppression model and reduces the bacterial load. Compared with a traditional electroporation method, the preparation method of the application significantly improves the encapsulation rate of siRNA.

The application belongs to the technical field of medical detection, and particularly relates to a polysaccharide contrast agent capable of renal metabolism and a preparation method thereof. The polysaccharide contrast agent has a structure as shown in formula (I), a particle size less than or equal to 8 nm, and can be rapidly metabolized through the kidney. The preparation method is to graft a metal macrocyclic ligand to a nano-crosslinked polysaccharide particle, and to prepare through a deprotection and metal ion chelation step. Since the contrast agent has the characteristic of renal metabolism, phagocytosis of the reticuloendothelial system is reduced, in vivo deposition of the contrast agent is reduced, and thus the biological safety is improved. Since a macrocyclic chelating ligand is used, good kinetic stability is achieved, the risk of in vivo metal ion deposition is reduced, and when applied to in vivo imaging, clear imaging of cardiovascular, lymph node, liver and other parts can be achieved. The preparation method is simple and easy to implement, reaction conditions are mild, is conducive to large-scale production and clinical transformation, and has a wide biomedical application prospect.

The invention discloses a preparation method of a bionic magnetic nano-motor mixed and wrapped by a neutrophile granulocyte membrane and a stem cell exosome. The bionic magnetic nano-motor comprises the neutrophile granulocyte membrane, the stem cell exosome, a polylactic acid-glycolic acid copolymer and an anti-inflammatory drug. According to the method, a layer of polylactic acid-glycolic acid copolymer is wrapped outside magnetic ferroferric oxide nanoparticles and an anti-inflammatory drug by utilizing an ultrasonic emulsification method, and finally the polylactic acid-glycolic acid copolymer is wrapped by utilizing a neutrophile granulocyte membrane and a stem cell exosome, so that the bionic magnetic nano motor is obtained, and the motor has good biocompatibility. Meanwhile, the motor has an immune escape function and can resist phagocytosis of macrophages in blood. And under the control of an external alternating magnetic field, the medicine can accurately reach a spinal cord injury part, and the effects of inflammation inhibition and neuron recovery can be achieved under the mixed action of neutrophile granulocyte membranes, stem cell exosomes and anti-inflammatory drugs.

The application belongs to the application field of selenium polysaccharide, and particularly relates to application of the selenium polysaccharide in preparation of an immune active agent, wherein the selenium polysaccharide is obtained by treating Cyclobalanopsis glauca with exogenous selenium, has good immune activity, can better promote proliferation and phagocytosis of RAW264.7 macrophages, and has a significant advantage in improving the release amount of NO, and the results show that the polysaccharide after exogenous selenium strengthening has better immune activity. Exogenous selenium strengthening obviously improves the characteristics of the selenium polysaccharide in Cyclobalanopsis glauca leaves, and has better potential in antioxidation and immune improvement, and provides data support for further research and utilization.

The instant application describes improved methods and compositions for the systemic delivery of therapeutic exosomes to a subject in need thereof. In certain embodiments, the current invention reduces the amount of exosomes delivered to liver, spleen and combinations thereof to allow greater distribution to other areas of the body such as, but not limited to, the brain, pancreas, lung, kidney, muscle. In certain embodiments, the methods involve the injection of one or multiple doses of non-therapeutic exosomes prior to the injection of a suitable therapeutic dose of exosomes with a therapeutic payload. Also included are methods to improve immune clearance of exosomes in subjects by inhibiting phagocytosis.

Antibodies that target VZV glycoprotein E (gE) bind to recombinant gE with high affinity, bind to gE on the surface of VZV infected cells, interact with immune system effectors (e.g., Fc receptors), mediate antibody-dependent cellular cytotoxicity (ADCC) as well as Antibody Dependent Cellular Phagocytosis (ADCP), and prevent VZV infection of cells.